Cementation of Cup and the Risk of Second Revision
Launched by BISPEBJERG HOSPITAL · Sep 2, 2024
Trial Information
Current as of November 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the method used to secure the acetabular component (the socket part of the hip joint) during the initial total hip replacement surgery affects the likelihood of needing a second surgery later on. The researchers are particularly interested in comparing two techniques: using cement to fix the cup in place versus not using cement. They want to see if one method leads to a higher risk of needing further revisions to the hip joint.
To take part in this study, participants should be between the ages of 65 and 74 and have had their first hip replacement due to primary osteoarthritis. They must have had a revision surgery where the liner or socket was replaced, and they should have specific sizes of the femoral component. However, those who only had the femoral component revised or have certain types of implants won’t be eligible. While the study is not yet recruiting participants, once it starts, those enrolled can expect to provide information about their surgeries and health, helping researchers understand the best practices for hip replacement surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary osteoarthritis as the indication for the primary THA.
- • Has experienced a first revision with exchange of the liner, femoral head and/or acetabular component either with or without exchange of the femoral component.
- • Femoral with a size of 28mm, 32mm or 36mm after the first revision
- • Surgery with the posterior approach.
- Exclusion Criteria:
- • Isolated revision of the femoral component.
- • Constrained liner.
- • Metal-on-metal implant.
About Bispebjerg Hospital
Bispebjerg Hospital is a leading healthcare institution located in Copenhagen, Denmark, renowned for its commitment to innovative medical research and clinical excellence. As a key sponsor of clinical trials, the hospital focuses on advancing healthcare by exploring novel therapies and treatment protocols across various medical disciplines. With a multidisciplinary team of experienced researchers and clinicians, Bispebjerg Hospital aims to enhance patient outcomes through rigorous scientific inquiry and evidence-based practices, while fostering collaboration with academic institutions and industry partners to drive progress in the medical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Søren Overgard, MD, PhD, DMSc
Study Director
Department of Orthopedic surgery and traumatology, Hvidovre Hospital, Copenhagen, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported